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I. Introduction 
Chronic disease states such as type 2 diabetes and cardiovascular disease are 
associated with low grade systemic and chronic inflammation (1). While inflammation is 
required for internal signaling, chronically, it can be destructive to the body. Therefore, 
chronic inflammation is a common area of interest for researchers.  With new 
technology, in the 1990’s we were able to further investigate how inflammation exists – 
by measuring the byproducts of inflammatory pathways, called oxylipins or lipid 
mediators. This paper focuses on the role of specific lipid mediators to understand their 
role in inflammation, specifically in type 2 diabetes. Further, we aim to explore how 
omega-3 supplementation can alter inflammation in a type 2 diabetic state. We will look 
closely at both the initiation and resolution phase of inflammation, which is propagated 
by lipid mediators.  
There are two types of inflammation, acute and chronic. Acute, transient 
inflammation is necessary (2).  It allows the body to send systemic signals for 
regeneration and repair. This is much like what is seen in exercise.  An individual’s 
muscle contracts, the body sends signals that a strenuous force is being exerted, and 
these signals regenerate the muscle and allow them to adapt - through increases in size 
or strength of muscle tissue. However, low-grade chronic inflammation is unnecessary 
and detrimental to the body. This type of systemic inflammation causes elevated levels 
of stress signals even without external stimulus. When these signals remain elevated 
over time, they can contribute to insulin resistance, type 2 diabetes, hypertension, 
atherosclerosis, and dyslipidemia, ultimately increasing rates of mortality (3). The 
reason for the cause of this inflammation is unknown and well-debated. However, 
investigating lipid mediators from these inflammatory pathways may provide insight.  
 
Polyunsaturated Fatty Acids 
Lipid mediators can be derived from polyunsaturated fatty acids (PUFAs), fatty acids 
with two or more double bonds.  The position of their double bonds categorize them as 
n-3 (omega-3) or n-6 (omega-6) fatty acids, based on the first double bond’s location 
from the terminal carbon. These are ingested in the form of fish, fish oils and nuts (n-3), 
and vegetable oils (n-6) among others (4).  Once ingested, these fatty acids undergo 
desaturation and elongation in the body, forming products such as arachidonic acid 
(AA), and, to a lesser extent, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid 
(DHA) (4). However, elongation and desaturation of precursors to AA, EPA, and DHA is 
not effective; thus, these fatty acids are considered conditionally essential. Traditionally, 
research has supported the idea that n-3 fatty acids are anti-inflammatory while n-6 fatty 
acids are pro-inflammatory. This is not generally the case as the paradigm on 
inflammation is shifting. There is emerging evidence that in some cases, n-6 fatty acids 
can be anti-inflammatory, and in some cases, n-3 fatty acids can be pro-inflammatory. 
However, for the purposes of this paper, we will focus on n-6 PUFAs in the initiation 
phase of inflammation, and n-3 PUFAs in the resolution phase.  
Under basal conditions, arachidonic acid is a main component of phospholipids and 
is incorporated cell membranes, such as those of brain, muscle, and liver cells (5). DHA 
and EPA are also incorporated into cell membranes, mainly in eye and brain cells (6). 
As needed, phospholipids in the cell membrane are cleaved by phospholipase A2.  The 
substrate for this enzyme (either AA, EPA, or DHA) is then released into the cytoplasm 
from the second carbon of the glycerol backbone (7). Individually, AA, EPA, or DHA go 
on to form lipid mediators through the enzymes COX (cyclooxygenase), LOX 
(lipoxygenase), and CYP (monooxygenase) (Figure 1).  Many of these downstream 
products cause an inflammatory response.  
 
Known Anti-Inflammatory Targets 
Blocking enzymes of inflammatory pathways have traditionally been the targets of 
research and pharmaceutical drugs such as corticosteroids and non-steroidal anti-
inflammatory drugs (NSAIDs).  These drugs inhibit phospholipase A2 and COX2, and 
therefore block the production of lipid mediators. However, in disease states such as 
type 2 diabetes, chronic inflammation still exists even after taking these medications. 
Moreover, the byproducts of these inflammatory pathways, lipid mediators, still remain 
even after blocking their upstream enzymes (Figure 1).  
Are lipid mediators regulating this chronic inflammation in type 2 diabetes? Only 
recently have we been able to accurately measure lipid mediators, and there is much 
we still do not know about their role. Some help to resolve inflammation, while others 
promote inflammation.   
 
Lipid Mediators Synthesized from n-3 and n-6 Fatty Acids 
Lipid mediators are oxylipins that include but are not limited to prostaglandins, 
thromboxanes, leukotrienes, lipoxins, and specialized pro-resolving lipid mediators. 
Their role has often been related to the function of hormones, where hormones are 
released from one location of the body, and carry out their function in another.  
However, compared to hormones, lipid mediators are produced in much smaller 
amounts, act locally, and are produced in almost all tissues. Their functions in the body 
include, but are not limited to, inflammation regulation, gastric integrity, renal function, 
smooth muscle contraction, blood vessel diameter, and platelet homeostasis (8). Lipid 
mediators carry out their role quickly, have a short half-life, and only require a small 
amount to elicit a powerful response.  After they carry out their purpose, they are rapidly 
metabolized and become inactive (8).  
As there are hundreds of lipid mediators, they are grouped by the substrate and by 
the enzyme in which they are derived from (9).  Different substrates i.e. EPA, DHA, and 
arachidonic acid lead to the production of different lipid mediators (9). In addition, 
different enzymes COX, LOX, and CYP, also lead to different combinations of 
downstream products.  Lipid mediators can also be synthesized by other PUFAs such 
as dihomo-y-linolenic acid, adrenic acid, linoleic acid, linolenic acid, etc. However, these 
lipid mediators are outside of the scope of this paper.  
This literature review will outline the initiation phase (dominated by arachidonic acid 
lipid mediators) and resolution phase of inflammation (dominated by DHA and EPA lipid 
mediators). In addition, we will look at type 2 diabetes, how specialized pro-resolving 
lipid mediators (SPMs) are affected in this disease state, and what effect omega-3 fatty 
acids can have on them. 
 
II. Methods:  
Background information was largely extracted from “Resolvins, Specialized Pro-
Resolving Lipid Mediators and their Potential Roles in Metabolic Disease” by Spite, 
Claria, and Serhan. Published articles were collected from PubMed and Google 
Scholar, keywords were: type 2 diabetes, lipid mediators, oxylipins, inflammation, 
omega-3, and combinations of these. 
 
III. Research: 
1. An Overview of Inflammation:  
 
 
 
Figure 1: Initiation à Resolution. Tissue injury leads to a vascular response causing 
arachidonic acid lipid mediators to be produced, i.e. PGE2, PGI2 (initiation).  
Neutrophil migration occurs.  Neutrophils clean up the damage through lysosomal 
apoptosis, but are small particles and ultimately die off. Arachidonic acid lipid 
mediators such as LTB4 activate the class switching of lipid mediators.  Monocytes 
are recruited to engulf apoptotic neutrophils, ultimately differentiating into 
macrophages.  M2 macrophages work to phagocytose any left damage and repair 
the inflammation. 
 
2. Initiation:  
 
 
Figure 2: Omega-3 (DHA, EPA) and omega-6 (AA) substrates are cleaved  
during tissue inflammation or injury, leading to lipid mediators.   
 
Acutely, inflammation progresses in two phases, initiation and resolution. The 
initiation phase marks the beginning of an inflammatory response, and is largely driven 
by arachidonic acid lipid mediators, also termed eicosanoids.  
During tissue injury or trauma, arachidonic is released from phospholipids within the 
cell membrane (10). Cytosolic phospholipase A2 cleaves arachidonic acid in the sn-2 
position of the glycerol backbone. Once released, arachidonic acid generally follows a 
cascade that produces pro-inflammatory lipid mediators, and leads to more 
inflammation, vasoconstriction, and proliferative effects (11).   
Early in the initiation phase, arachidonic acid can be enzymatically converted by the 
COX enzyme to PGE2. This lipid mediator along with others (i.e. PGI2) drives immune 
cell migration and promotes the beginning of an inflammatory response (10). As the first 
immune cells, apoptotic neutrophils migrate to the area of trauma, LTB4 concentrations 
are at their peak, amplifying the recruitment signal.  PGE2 and PGD2 gradually work to 
stimulate the synthesis of LXA4. When the neutrophils have completed their task, LXA4 
(an SPM but synthesized from arachidonic acid) is present and appears to act as a stop 
signal, stopping any additional neutrophils from migrating to the area.  This allows 
regenerative immune cells to arrive. PGE2 and PGD2 also promote a class switching of 
lipid mediators from pro-inflammatory (arachidonic acid substrates) to anti-inflammatory 
(SPMs). Lipoxins (pro-resolving lipid mediators) carry out their role, activate pro-
resolving mediators to step in, and then are rapidly metabolized and become inactive 
(10).  
It is important to note that this phase of inflammation is an acute response, and 
plays a vital role in signaling injury or trauma by drawing immune cells (i.e. apoptotic 
neutrophils, monocytes, macrophages) toward the injury, resolving the trauma, and 
resuming homeostasis.  The signals of initiation and resolution are tightly linked to 
downstream mediators. Therefore, in order to resolve inflammation, initiation is 
imperative because it will signal the resolution phase (12). When these signaling 
patterns are altered over time, complications can occur as described below with type 2 
diabetes. 
 
3. Resolution:  
 
Figure 3: The resolution phase has different inflammatory responses in a timely 
manner. Edema occurs in seconds-minutes, PMN infiltration occurs in seconds-minutes, 
and monocyte/macrophage recruitment occurs in seconds and ends during the 
resolution phase. 
 
 Lipid mediators derived from EPA and DHA are largely generated in the 
resolution phase.  EPA produces resolvins, while DHA produces protectins, maresins, 
and resolvins (13).  Collectively, these lipid mediators are known as SPMs, or 
specialized pro-resolving lipid mediators, and work to stop the initiation phase and 
resolve any inflammation present. 
Once apoptotic neutrophils have come to the site of inflammation, monocytes are 
needed to pick them up and package them away for phagocytic degradation. As 
monocytes continue to clean up necrotic neutrophils and cellular debri, they become 
larger macrophages. PGE2 and PGD2 increase SPM migration toward the tissue injury 
when macrophages are in the process of engulfing and clearing apoptotic neutrophils 
(14). In addition, the act of macrophage phagocytosis alone stimulates the biosynthesis 
of pro-resolving lipid mediators which further promote phagocytosis (10).  Overall, when 
SPMs are released, they work to cease neutrophil migration, decrease pro-inflammatory 
cytokines and lipid mediators, and stimulate neutrophil uptake by macrophages (12).  
Macrophage clearance of neutrophils and cellular debri relieves the inflammatory 
response, and helps resume homeostasis. 
Resolvins, protectins and maresins are SPMs. EPA produces E-series resolvins (i.e. 
RvE1, RvE2 and RvE3). DHA produces D-series resolvins (i.e. RvD1, RvD2), protectins 
(i.e. PD1 and (N)PD1) and maresins (MaR1), among many others.  
When ingesting dietary omega-3, EPA or DHA, these substrates can out-compete 
AA by blocking AA formation and by taking the place of AA in cell membrane 
phospholipids (15).  Therefore, when a tissue injury is present, EPA and DHA are 
cleaved by phospholipase A2 instead of AA. Thus, leading to more anti-inflammatory 
lipid mediators such as resolvins, protectins, and maresins. This produces a balance of 
anti-inflammatory and pro-inflammatory lipid mediators, and is a preferred outcome (15).  
Data suggest humans taking omega-3 supplements can generate SPMs, and SPMs are 
also increased in transgenic mice who express an omega-3 fatty acid desaturase (16). 
However, data on the ingestion of omega-3 supplements have been inconsistent, 
requiring the need for more research in this area.   
This paper will focus on lipid mediators in the resolution phase that may be deficient 
in type 2 diabetic populations.  Moreover, we will discuss the effect of omega-3 
supplementation in a type 2 diabetic disease state.  
 
4. Type 2 Diabetes, SPM Deficiency: 
Unresolved acute inflammatory responses can lead to chronic inflammation, which is 
a major driver of disease. When unresolved, the dysfunctional metabolic environment in 
type 2 diabetes promotes apoptotic neutrophil and monocyte (leukocyte) infiltration over 
time (10). When this persists, a continued apoptotic neutrophil presence can create a 
negative cascade and unintentionally lead to tissue damage or death (10)(13). In 
addition, this type of chronic inflammation seen in patients with type 2 diabetes and is 
commonly associated with other co-morbidities such as hypertension, dyslipidemia, 
atherosclerosis, and heart disease (10).  
Typically, the initiation phase of inflammation is not dysfunctional, but the bodies’ 
ability to resolve it is. Thus, SPMs, which are largely present in the resolution phase of 
inflammation are considered deficient in those with chronic diseases such as type 2 
diabetes. This deficiency is due to impaired biosynthetic processes (17). Therefore, 
SPMs are important lipid mediators to measure and research in this population.  
Restoring the resolution phase could, in turn, resolve inflammation.  
While measuring baseline values of SPMs in patients with type 2 diabetes is helpful, 
measuring a ratio of SPMs to prostaglandins and leukotrienes depicts a better overall 
status of inflammation in the body.  For example, if SPM (the anti-inflammatory 
biomarkers) levels are found to be high in patients, this could be seen as beneficial. 
However, if the measure of leukotrienes and prostaglandins (pro-inflammatory 
biomarkers) are even higher than SPMs, than solely measuring SPMs could skew our 
perception of inflammatory status.  Therefore, it is ideal to measure both the SPMs, the 
leukotrienes and prostaglandins, and a portray them as a ratio for an accurate 
inflammatory measure. 
This section highlights root areas where patients with type 2 diabetes have a 
dysfunctional resolution phase of inflammation and are thus deficient in SPM lipid 
mediators. In the next section, we address ways to rescue these deficiencies. 
 
Insulin Signaling  
 Patients with type 2 diabetes have impaired insulin signaling. As glucose levels 
remain elevated over time, insulin compensates for this by also remaining elevated.  As 
time progresses, the pancreas becomes overwhelmed by the amount of insulin it is 
producing, and the ability of the pancreas to release enough insulin to compensate for 
the high glucose levels is impaired. Signaling along the insulin cascade is also 
dysfunctional, as instead of tyrosine phosphorylation which would allow Akt production, 
serine residues are inappropriately phosphorylated.  Ultimately, this leads to an 
impaired final signal for insulin action.  
 
Free Fatty Acids 
High levels of free fatty acids (FFA) which are non-esterified in the blood are 
associated with type 2 diabetes.  As glycemic control worsens, circulating free fatty 
acids in the blood are increased.  This is due to decreased insulin signaling, poor 
glucose uptake, and the body adapting to use triglycerides as an alternative fuel source 
through increased lipolysis (18).  Increases in these circulating FFAs in the blood drives 
acute and chronic macrophage recruitment leading to chronic inflammatory signaling 
over time (19).  When free fatty acids are in a saturated form, they bolster immune cell 
activation, the production of inflammatory cytokines, and the survival of apoptotic 
neutrophils during acute inflammation which in turn lead to insulin resistance (20)(21). 
However, the notion that saturated fatty acids are driving insulin resistance through 
inflammatory pathways remains debated. 
 
Efferocytosis 
 Macrophages from ob/ob and db/db mice have dysfunctional and inefficient 
efferocytosis, which is the ability of macrophages to engulf and eliminate apoptotic 
neutrophils (22). In Lu et al’s study, efferocytosis of macrophages of control mice was 
coupled with an increase in PI3k and Akt phosphorylation, thus leading to insulin 
sensitivity. However, ob/ob macrophages had significantly impaired PI3k and Akt 
signaling during efferocytosis at baseline (22). 
 
Inflammatory Cytokines 
 In some, but not all cases, obesity is associated with type 2 diabetes.  As seen in 
obesity, white adipocytes can expand to create much larger adipocytes during nutrient 
excess (23).  As these adipocytes get larger, they can inadvertently trigger hypoxia, 
which can lead to low-grade inflammation through activation of inflammatory cytokines.  
Increases in inflammatory cytokines TNFα, IL-6, IL-1β, MCP-1, and leptin, as well as a 
reduction in adiponectin, have reported correlating with the expansion of white adipose 
tissue (24). With these circulating inflammatory cytokines comes the recruitment of 
immune cells such as macrophages in white adipose tissues which perpetuate an 
inflammatory response (10).  In patients and experimental models of obesity and insulin 
resistance, there is a deficiency of SPMs (25). Specifically, in both ob/ob and db/db 
mice there are deficient levels of RvD1 (resolvin D1), PD1 (protectin D1), and 17-HDHA 
(17-hydroxy docosahexaenoic acid) SPMs in inflamed adipose tissue (26)(27).  
 
Diabetic Wounds 
Poor wound healing is associated with type 2 diabetes. There are over 100 known 
factors that contribute to this, such as impaired growth factor production, impaired 
macrophage function, peripheral neuropathy, insufficient blood supply, and others 
(28)(10). For instance, Tang et al. found that there is a consistent delay in wound 
healing among diabetic mice and a deficiency of RvD1. As this is a common long-term 
complication of diabetic patients, and a frequent hospital visit chief complaint, resolving 
inflammation to reduce the presence of wounds is a high priority (29). 
 
 
5. Role of Diet: Can omega-3 rescue SPM deficiencies? 
Omega-3 fatty acid insufficiency has been linked to the incidence of metabolic 
disorders such as type 2 diabetes (30). Therefore, it has been predicted that omega-3 
supplementation would amplify substrate availability for the production of pro-resolving 
lipid mediators.  In turn, this would rescue the SPM deficiencies seen in type 2 diabetes 
and other chronic disease states. Research below was gathered on omega-3 or SPM 
supplementation, and their effect on lipid mediator production in patients with type 2 
diabetes.  
There are many studies that suggest supplementation with omega-3 fatty acids, EPA 
and DHA, can rescue this SPM deficiency, and in turn the resolution phase, allowing for 
both acute and chronic inflammation to resolve.  However, the research remains 
inconclusive.  This section outlines the current research on this subject.  
 
Insulin Signaling 
 Hellman et al. demonstrated that administration of RvD1 to db/db diabetic mice 
improves insulin-stimulated Akt phosphorylation in adipose tissue, improved glucose 
tolerance, decreased fasting blood sugars, and decreased the amount of macrophage 
abundant crown-like structures in adipose tissue (31).  In another experiment where an 
intraperitoneal injection of RvE1 in ob/ob mice was given, the AMPK-adiponectin 
pathway was activated, along with increases in the expression of GLUT-4 and IRS-1 
(32). With this same experiment, an injection of 17-HDHA into the intraperitoneal cavity 
improves glucose tolerance through restoring insulin sensitivity (27).  
 
Free Fatty Acids 
 Free fatty acids in the bloodstream have negative consequences, leading to 
defective uptake of apoptotic cells by macrophages (10). Some strategies to alleviate 
the inflammation and improve immunity caused by circulating free fatty acids are 
available. Li et al found that the addition of EPA and DHA may play an important role in 
the resolution of inflammation propagated by free fatty acids within circulation (22). 
Saturated free fatty acids induced a defect in PI3k activation of macrophages in 
controls, while EPA relieved the defect of PI3k activation on macrophages in ob/ob 
mice. As PI3k is along the insulin cascade, ultimately activating Akt and carrying out the 
effects of insulin, this shows improved insulin sensitivity.  Maresin 1 also reduces 
lipolysis through the action of inhibition of TNFα in ex vivo adipocytes (33). 
 
Efferocytosis 
Ob/ob mice are great models for insulin resistance and have been extensively 
used to simulate type 2 diabetic disease states (34). In using these mice, Li et al. found 
that when ob/ob mice were fed EPA-albumin complexes, there was an improvement in 
efferocytosis. When ob control mice and ob/ob mice were given olive oil or fish oil 
supplements for about a month, efficiency of efferocytosis was decreased significantly 
in ob/ob olive oil-treated mice compared to control, and this was reversed in fish oil-
treated mice compared to the control (22).  The fish oil supplemented mice also had 
significant improvements in Akt phosphorylation, the cascade for insulin signaling (22). 
Dysfunctional efferocytosis can also be reversed by resolvin D1 (RvD1) in a mouse 
model as shown by Tang et al (29).  Treatment with RvD1 decreased the accumulation 
of lymphocytes and enhanced macrophage phagocytosis diabetic mice (29).  
Alternatively, RvE1 supplementation is shown to enhance the phagocytosis, 
killing, and clearance of a bacteria (P. gingivalis) in control mice, but not in the type 2 
diabetes db/db mouse model in a 2015 study with Herrera et al (35).  
 
Inflammatory Cytokines 
In a study conducted by White et al., high fat-fed obese mice were given a dose 
of TNFα which triggered an inflammatory response. Protectin D1 in this experiment was 
able to restore the resolution phase of inflammation, and prevent macrophage migration 
in mice (30). In another mouse model, RvD2 inhibited plasma cytokines such as TNFα, 
IL-1β, and neutrophil platelet-endothelial cell adhesion molecule-1 (36). Both RvD1 and 
RvD2 increased adiponectin levels in ex vivo fat explants, while also decreasing leptin, 
TNFα, IL-6, and IL-1β (37). MaR1-treated db/db mice decreased adiposity, leptin, MCP-
1, TNFα, and IL-1β expression.  In addition, adiponectin, GLUT4 expression were 
upregulated as well as Akt and AMPK phosphorylation in adipocytes. (38)  Introduction 
of 17-HDHA into the intraperitoneal cavity of db/db mice reduced the expression of 
MCP-1, TNFα, and IL-6 (27).   
In more recent studies (2015 and 2017) DHA and EPA both significantly 
increased PPARγ synthesis in human and mouse cell cultures, thus stimulating 
adiponectin synthesis and secretion (39)(40). In both studies, cells were treated for 24 
hours.  However, there is also evidence from a double-blind study with 162 end-stage 
renal disease patients in 2015 that suggests adiponectin levels do not increase with 
three-month supplementation of n-3 PUFAs (41). In 2017 a double-blind study also 
revealed no changes in human inflammatory biomarkers, lipid levels, adiponectin, leptin, 
or resolvin D1 when supplementing 1 gram/day of EPA plus 1 gram/day of DHA for 3 
months (42). 
 
Diabetic Wounds 
 Conversion of DHA to RvD1 in a diabetic mouse model (db/db) accelerated 
wound closure and allowed for less apoptotic neutrophils and macrophages at the site 
of the wound (29).  A wound was produced, and 24 hours later, RvD1 was topically 
applied to the wound, with the administration of 4 injections intra-dermally each day.  
Those treated with RvD1 after 8 days had a significantly smaller wound diameter, along 
with more granulated tissue formation compared to controls (29). In mice, RvD1 also 
enhances a critical step in wound closure, specifically, human keratinocyte migration 
(43). 
 Bohr et al. also addressed resolvin supplementation in the mouse model by 
supplementing resolvin D2 (RvD2) to burn injuries.  Although RvD2 was found to 
increase the accumulation of neutrophils in treated wounds, it also prevented secondary 
vascular thrombosis (36). Moreover, Kurihara et al found that in a burn model 
experiment with rats, neutrophil motility and directionality were impaired. However, 
RvD1 and RvD2 both restored directional motility of neutrophils. These defects could 
also be restored in vivo after 7 days of RvD2 administration. Of note, post- 7 day RvD2 
supplementation not only corrected neutrophil motility and directionality, but also 
correspondingly significantly improved survival of burn-injured rats, even after septic 
insults (44). 
 More recently, a comparison of three lipid mediators - RvD1, RvD2 and RvE1 
was accomplished by using each in inflammatory and injury settings. Specifically, these 
lipid mediators were compared on their ability to inhibit neutrophil migration and 
determine whether this has an effect on wound healing (17).  Neutrophil migration was 
most significantly decreased compared to the control when all lipid mediators (RvD1, 
RvD2, RvE1) were supplemented, and to the greatest extent, with RvE1 (17).  RvE1 
was the only resolvin to show a stronger effect at higher concentrations (when 
increased from 500 nM to 2,000 nM) however, no changes were seen in doses beyond 
500 nM for RvD2 and RvE1 (17).  
 
6. Clinical Trials: Effect of omega-3 on Patients with Type 2 Diabetes 
 
Exercise and Type 2 Diabetes 
In a randomized control trial with two groups, 15 participants took a gelatin 
placebo and 15 participants took 180mg of EPA and 120mg of DHA for 8 weeks.  At the 
beginning and end of the protocol, a cycling test was performed. The test started with a 
25 W load, with 25 W per minute increases until exhaustion.  Supplementation with n-3 
PUFAs DHA and EPA significantly reduced triglyceride levels, but did not have an effect 
on inflammation or oxidative stress (45). 
 
Gestational Diabetes 
40 participants aged 18-40 years old were involved in a randomized control trial 
lasting 6 weeks.  20 participants were in the placebo group, and 20 participants were in 
a group taking fish oil capsules containing 180mg EPA and 120mg DHA 2 times a day.  
Those in the fish oil supplementation group did not have significant differences in serum 
insulin, total cholesterol levels, or HOMA-IR compared to the placebo after 6 weeks. 
However, fasting plasma glucose and triglyceride levels were significantly decreased. 
PPARγ was upregulated in participants taking fish oil. In terms of inflammation, IL-1 and 
TNFα were significantly downregulated in the fish oil supplementation group (46). 
 
Type 2 Diabetes 
In Toluca, Mexico, 65 participants with low SES and type 2 diabetes were 
randomly assigned to a placebo group (31) or fish oil supplementation group (34).  The 
supplementation group took 2 pills per day consisting of 160mg EPA and 100mg DHA 
for 24 weeks (250mg/day total). This study was a single-blind study. There were 
significant decreases in HbA1c, leptin, and leptin/adiponectin in both groups, however, 
serum glucose levels were only decreased in the fish oil supplementation group. No 
significant differences were seen in serum insulin or HOMA-IR.  Triglycerides and 
atherogenic index were significantly decreased in the supplementation group (47). 
 
In Syndey, Nova Scotia, a double-blind randomized control trial was carried out 
among participants 18 years of age or older. Each participant was their own control for 
the first 3 months of the trial, then interventions of both low ALA safflower oil (1g gelatin 
capsules, 14 participants) and high ALA flaxseed oil (60mg ALA/kg body weight/day, 18 
participants) were given. There were no significant changes in glucose, insulin, HOMA-
IR, or HOMA-%β -percent remaining beta cell function (48). 
 
72 type 2 diabetic participants aged 30-70 years old were involved in a double-
blind randomized control trial.  The supplementation group of 36 participants received a 
softgel containing 362.5mg DHA and 100mg EPA 4 times per day for 8 weeks, and 
there was a placebo-control group consisting of 36 participants. No significant 
differences were seen in dietary intake across the study based on 3-day diet records. 
Both waist circumference and waist to hip ratio, as well as triglyceride levels were all 
significantly decreased in the intervention group.  Changes in serum insulin, HOMA-IR, 
and fasting blood sugar were not statistically significant.  sCD163 has been identified as 
a macrophage activator and is elevated in type 2 diabetic states as well as other 
inflammatory diseases (58). Supplementation with fish oil was shown to significantly 
decrease sCD163 as well (49). 
 
A double-blind, randomized control trial with type 2 diabetes patients was 
conducted with 20 patients receiving ALA at 3g per day or placebo.  Participants were 
aged 30-65 years old, and the study intervention lasted 60 days.  At the end of 60 days, 
no significant changes were observed in serum IL-1, IL-6, TNFα, CRP, fasting plasma 
glucose, insulin, HbA1c, or HOMA-IR. At the end of 60 days, adiponectin increased 
significantly in both groups (50).  
 
An 8-week single-blind randomized control trial was carried out among 59 
subjects with early-stage type 2 diabetes or metabolic syndrome.  Interventions included 
corn oil, botanical oil, or fish oil. Those in the fish oil intervention group at the end of the 
trial had significantly lower levels of triglycerides, and an increase in HDL cholesterol, 
and an increase in insulin. Fish oil did not have a statistically significant effect on fasting 
glucose levels, but did have a significant effect on HbA1c by decreasing it.  C-reactive 
protein changes were not statistically significant, however, they did have a downward 
trend (51).  
 
Many of these clinical trials reach the gold standard criteria in terms of research 
design.  They are randomized, double-blinded, placebo-controlled, and have a relatively 
high sample size for this type of study.  However, all clinical trials mentioned have some 
research failures in terms of design.  For example, many of the studies have a high 
percentage of women enrolled in the study, or the opposite, a high male participation 
rate.  This does not account for gender differences between men and women, such as 
diabetic women having lower rates of diabetes medication efficacy, or diabetic women 
being at greater risk of morbidity and mortality (52).  These factors and others could 
skew the results of a study where men and women are not isolated. 
Genetic differences, stage of type 2 diabetes, and age also play a vital role. If 
one individual metabolizes glucose more efficiently than another, this will skew the 
results regardless of the intervention. Moreover, if someone has just been diagnosed 
with diabetes, they may fare better with a dietary intervention than someone who has 
had diabetes for 40 years and is receiving insulin. Age also makes a great difference. 
Some of the age ranges of participants in these studies were 30-70 years old, or 25-60 
years old. These ranges encompass many different stages and styles of life and even 
greater diet and metabolism differences.  
In addition, where the study was completed also makes a difference in terms of 
which study can be generalizable to other populations.  For example, one study was 
completed in Mexico, one in Canada, and another in Iran.  These studies may only be 
generalizable to those respective countries as the cuisine, culture, and environment are 
specific to that area.  Clinical trials moving forward should consider these areas when 
developing an omega-3 intervention for type 2 diabetes. 
 
IV. Conclusion: 
In the last 20 years, the number of adults with type 2 diabetes has tripled. Diabetes 
is the 7th leading cause of death in the United States (53).  For these reasons, it is a 
great public health concern. As systemic inflammation is associated with type 2 
diabetes, understanding inflammation and how it exists in can help us understand ways 
to mitigate it.  In addition, new therapeutic approaches are needed for disease states 
where inflammation persists to the point of organ dysfunction. Therefore, we researched 
the literature on the effect of omega-3 supplements as well as the derivatives EPA and 
DHA in the resolution phase of SPMs in type 2 diabetes.  
As new research equipment has only recently become available, and therefore a 
thorough investigation of lipid mediators is only beginning, we are still learning the 
properties of lipid mediators and the role they play in inflammation.  We know that lipid 
mediators play a vital role in the acute inflammatory response. They draw apoptotic 
neutrophils to the affected area, direct the lipid mediator switch from pro-inflammatory to 
anti-inflammatory and signal macrophages to engulf them (10).  After carrying out their 
purpose they are immediately degraded and become inactive (8).  
In regard to the role they play in diabetes, there is much more to be discovered.  
Overall, patients with type 2 diabetics typically have a dysfunctional resolution phase, 
where SPMs are significantly elevated, but they are unable to rescue the overwhelming 
amount of pro-inflammatory lipid mediators present, such as prostaglandins and 
leukotrienes. Thus, the ratio of anti-inflammatory to pro-inflammatory lipid mediators is 
skewed.  This leads to chronic inflammation over time. This paper points out several 
specific lipid mediators that are deficient in patients with type 2 diabetes such as RvD1, 
PD1, and 17-HDHA among others that lead to dysfunctional fatty acid metabolism, 
efferocytosis, cytokine production, and diabetic wounds.  
Research studies regarding the supplementation of lipid mediators to benefit 
patients with type 2 diabetes is a new and emerging area of research.  Studies in this 
area are scarce, but some show promising data in terms of rescuing the resolution 
phase of inflammation. 
Supplementation with either omega-3’s, DHA, or EPA within clinical trials is also an 
area in need of further exploration.  Although clinical trials are extensive, the research 
available remains inconclusive.  However, there are many flaws within the clinical trials 
which may skew the data such as the age of the population being studied, genetic and 
sex-based variances. Based on the evidence reviewed, omega-3s and their derivatives 
have the potential to aid in inflammation and improve other biomarkers of type 2 
diabetes such as insulin resistance.  
Diet can affect the majority of modifiable risk factors for type 2 diabetes as well as 
cardiovascular disease and cancer. Dietitians can play an instrumental role in facilitating 
meaningful lifestyle changes in these chronic diseases.  As such, we should remain up 
to date on omega-3 (DHA and EPA) as well as lipid mediator supplementation in 
rescuing these diseases.  At the very least, SPMs could have the therapeutic potential 
of rescuing dysfunctional fatty acid metabolism, insulin sensitivity, efferocytosis, 
cytokine production, and diabetic wounds.  
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